For: | Huang YJ, Cao ZF, Wang J, Yang J, Wei YJ, Tang YC, Cheng YX, Zhou J, Zhang ZX. Why MUC16 mutations lead to a better prognosis: A study based on The Cancer Genome Atlas gastric cancer cohort. World J Clin Cases 2021; 9(17): 4143-4158 [PMID: 34141777 DOI: 10.12998/wjcc.v9.i17.4143] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v9/i17/4143.htm |
Number | Citing Articles |
1 |
Yuqing Lou, Qin Shi, Yanwei Zhang, Ying Qi, Wei Zhang, Huimin Wang, Jun Lu, Baohui Han, Hua Zhong. Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia Signals. Frontiers in Cell and Developmental Biology 2022; 10 doi: 10.3389/fcell.2022.840466
|
2 |
Ryia Illani Mohd Yunos, Nurul-Syakima Ab Mutalib, Jia-shiun Khoo, Sazuita Saidin, Muhiddin Ishak, Saiful Effendi Syafruddin, Francis Yew Fu Tieng, Najwa Farhah Md Yusof, Mohd Ridhwan Abd Razak, Norshahidah Mahamad Nadzir, Nadiah Abu, Isa Md Rose, Ismail Sagap, Luqman Mazlan, Rahman Jamal. Whole genome sequencing of Malaysian colorectal cancer patients reveals specific druggable somatic mutations. Frontiers in Molecular Biosciences 2023; 9 doi: 10.3389/fmolb.2022.997747
|
3 |
Mengqi Song, Haoyue Cheng, Hao Zou, Kai Ma, Lianfang Lu, Qian Wei, Zejiang Xu, Zirui Tang, Yuanzheng Zhang, Yinan Wang, Chuandong Sun. Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-12407-2
|
4 |
Natarajan Saravanakumar, Arunagiri Sivanesan Aruna Poorani, Anantha Krishnan Dhanabalan, Selvam Sugapriya, Ganesan Kumaresan, Palaniswamy Suresh. Novel Fused Pyrimidines as Potent Cyclin‐Dependent Kinases Inhibitor for Gastric Adenocarcinoma: Combined In Vitro, In Silico Anticancer Studies. Chemical Biology & Drug Design 2024; 104(5) doi: 10.1111/cbdd.70013
|
5 |
Bing Liu, Zhicheng Dong, Yingzhi Lu, Jianhua Ma, Zhaoming Ma, Hongwei Wang, Weiguo Li. Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients. Evidence-Based Complementary and Alternative Medicine 2022; 2022: 1 doi: 10.1155/2022/3478861
|
6 |
Chengcheng Liu, Yuying Huo, Yansong Zhang, Fumei Yin, Taoyu Chen, Zhenyi Wang, Juntao Gao, Peng Jin, Xiangyu Li, Minglei Shi, Michael Q. Zhang. Development and Experimental Validation of a Novel Prognostic Signature for Gastric Cancer. Cancers 2023; 15(5): 1610 doi: 10.3390/cancers15051610
|
7 |
Isabella Kuniko T. M. Takenaka, Thais F. Bartelli, Alexandre Defelicibus, Juan M. Sendoya, Mariano Golubicki, Juan Robbio, Marianna S. Serpa, Gabriela P. Branco, Luana B. C. Santos, Laura C. L. Claro, Gabriel Oliveira dos Santos, Bruna E. C. Kupper, Israel T. da Silva, Andrea S. Llera, Celso A. L. de Mello, Rachel P. Riechelmann, Emmanuel Dias-Neto, Soledad Iseas, Samuel Aguiar, Diana Noronha Nunes. Exome and Tissue-Associated Microbiota as Predictive Markers of Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.809441
|
8 |
Joseba Elizazu, Aizpea Artetxe-Zurutuza, Maddalen Otaegi-Ugartemendia, Veronica Moncho-Amor, Manuel Moreno-Valladares, Ander Matheu, Estefania Carrasco-Garcia. Identification of a novel gene signature related to prognosis and metastasis in gastric cancer. Cellular Oncology 2024; 47(4): 1355 doi: 10.1007/s13402-024-00932-y
|